"Take More Risks, Fail Earlier" Says Asset-Hunting Novo Nordisk CEO
Executive Summary
Novo Nordisk's CEO tells Scrip why the Danish group's R&D approach must embrace risk earlier to ensure "differentiated" products in an increasingly competitive world.
You may also be interested in...
Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix
Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.
Novo Nordisk Names Jørgensen CEO As Sørensen Steps Down Early
Lars Rebien Sørensen is retiring as CEO of Novo Nordisk by the end of the year, with executive vice president and corporate development head Lars Fruergaard Jørgensen stepping up as his successor.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.